Voyageur Pharmaceuticals, led by CEO Brent Willis, has secured a $1.9 million sales contract for Latin America. The exclusive agreement with a radiology drug distribution partner covers two countries and includes incentives for sales growth. SmoothX®2% w/v, the company's flagship product for CT imaging, will lead market entry, with strong patient preference indicating promising market potential. This contract signifies a significant milestone for Voyageur Pharmaceuticals, setting the stage for expansion in Latin America.